Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ZLAB vs CGON: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CGON Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 5–3 Matrix Metrics)

CGON Overall Winner 6-Pillar Tally: ZLAB 3 – 3 CGON Matrix Metrics: ZLAB 3 – 5 CGON

As of Nov 16, 2026, CG Oncology, Inc. (CGON) is the stronger overall head-to-head candidate over Zai Lab Limited (ZLAB) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). ZLAB carries a Unified Composite Score of 47.4/100 (HOLD) at $23.83 (N/M Forward P/E, -63.0% operating margin), whereas CGON carries 45.0/100 (HOLD) at $84.94 (N/M Forward P/E, -4293.5% operating margin).

  • Composite vs. Pillar Nuance: While ZLAB currently prints a higher short-term Unified Composite Score (47.4/100 HOLD vs. CGON 45.0/100 HOLD), CGON captures the overall institutional head-to-head verdict (5–3 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (-4293.5% vs. -63.0% operating margin) and revenue trajectory (-3.7% vs. -6.8% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ZLAB vs CGON
ZLAB NASDAQ
Zai Lab Limited American Depositary Shares
Pharmaceutical Preparations
$23.83
-3.13% 1D
Market Cap $3.0B
TTM Revenue $442M
Forward P/E N/M
Beta / 30D Vol 1.19β · 78% Vol
Unified Composite Score
47.4 / 100 HOLD
Tech 25.0 Fund 39.0 Flow 50.0 Mom 53.5
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.1 · SMA20: $23.97 · SMA50: $24.57
CGON NASDAQ Head-to-Head Winner
CG Oncology, Inc. Common stock
Biological Products, (No Disgnostic Substances)
$84.94
+14.16% 1D
Market Cap $6.3B
TTM Revenue $6.2M
Forward P/E N/M
Beta / 30D Vol 0.77β · 86% Vol
Unified Composite Score
45.0 / 100 HOLD
Tech 15.0 Fund 44.0 Flow 69.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 72
RSI-14: 71.7 · SMA20: $67.45 · SMA50: $68.25

6-Pillar Scorecard Institutional Category Breakdown (ZLAB 3 – 3 CGON)

Columns: Metric · ZLAB · CGON
1. Valuation Multiples ZLAB
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 6.8x N/M
2. Growth & Scale CGON
Revenue Growth (YoY) -6.8% -3.7%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $442M $6.2M
Market Cap $3.0B $6.3B
3. Profitability & Quality ZLAB
Gross Margin 0.6% N/A
Operating Margin -63.0% -4293.5%
Net Profit Margin -44.9% 0.0%
Return on Equity (ROE) -30.0% -28.3%
4. Balance Sheet & Cash Flow CGON
Cash Generation (TTM) -$262M EBITDA -$189M
Cash Flow Margin -59.3% EBITDA Mgn N/A
Net Cash / Leverage $5.01 Book/Sh · -30.0% ROE $19M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CGON
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 58.4% (58th %ile) 238.6% (85th %ile)
Put/Call OI Skew Thin ADR Chain 0.35x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat ZLAB
OpEx & R&D Intensity 63.6% of Rev ($281M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ZLAB (3) vs CGON (5)
Institutional Metric ZLAB CGON Criterion Row Edge
Market Capitalization
Scale
$3.0B $6.3B Larger Scale CGON
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-6.8% -3.7% Higher Growth CGON
Operating Margin (TTM)
Profitability
-63.0% -4293.5% Higher Margin ZLAB
Net Profit Margin
Profitability
-44.9% 0.0% Higher Margin CGON
Return on Equity (ROE)
Capital Efficiency
-30.0% -28.3% Higher ROE CGON
52-Week Range Position
Momentum
60% ($16–$29) 84% ($37–$94) Stronger Trend CGON
Beta / 30D Volatility
Risk Regime
1.19β · 78% Vol 0.77β · 86% Vol Lower Realized Risk ZLAB
Unified Institutional Score
Composite Signal
47.4 / 100 (HOLD) 45.0 / 100 (HOLD) Higher Composite ZLAB
Trailing 12M Revenue (USD)
Operating Scale
$442M $6.2M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
0.6% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 6.8x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$262M EBITDA ($5.01 Book/Sh · -30.0% ROE) -$189M ($19M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CGON +39.15 pp
ZLAB: +2.76% · CGON: +41.91%
3M Horizon CGON +18.13 pp
ZLAB: -6.8% · CGON: +11.33%
6M Horizon CGON +8.62 pp
ZLAB: +26.35% · CGON: +34.97%
1Y Horizon CGON +115.27 pp
ZLAB: +9.66% · CGON: +124.93%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ZLAB vs CGON. Trailing 12-month operating profitability (ZLAB -63.0% vs CGON -4293.5%) and valuation multiples (ZLAB N/M vs CGON N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ZLAB ADR TTM Benchmark FX-Normalized USD
TTM Revenue$442M
Gross Margin0.6%
Op. Margin-63.0%
ROE / Fwd P/E-30.0% · N/M
CGON ADR TTM Benchmark FX-Normalized USD
TTM Revenue$6.2M
Gross MarginN/A
Op. Margin-4293.5%
ROE / Fwd P/E-28.3% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ZLAB UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 58.4%
IV Percentile 58th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ZLAB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CGON CONSOLIDATION
62d in phase · OBV ACCUMULATION
Current IV 238.6%
IV Percentile 85th %ile
Put/Call OI Skew 0.35x (Call-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact CGON Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ZLAB Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.0B market capitalization and -63.0% operating margin.
OpEx & R&D Reinvestment 63.6% of Rev ($281M)
90D Engineering Disclosures 0 Published
CGON Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $6.3B market capitalization and -4293.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ZLAB vs CGON Key Questions & Quantitative Answers

As of Nov 16, 2026, CG Oncology, Inc. (CGON) is the stronger overall head-to-head candidate over Zai Lab Limited (ZLAB) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). ZLAB carries a Unified Composite Score of 47.4/100 (HOLD) at $23.83 (N/M Forward P/E, -63.0% operating margin), whereas CGON carries 45.0/100 (HOLD) at $84.94 (N/M Forward P/E, -4293.5% operating margin). Composite vs. Pillar Nuance: While ZLAB currently prints a higher short-term Unified Composite Score (47.4/100 HOLD vs. CGON 45.0/100 HOLD), CGON captures the overall institutional head-to-head verdict (5–3 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (-4293.5% vs. -63.0% operating margin) and revenue trajectory (-3.7% vs. -6.8% YoY).

CGON leads the Growth & Scale pillar: ZLAB posts -6.8% YoY revenue growth and +0.0% YoY earnings growth on $442M TTM revenue (0.6% gross margin, -63.0% operating margin), compared with CGON at -3.7% YoY revenue growth and +0.0% YoY earnings growth on $6.2M TTM revenue (N/A gross margin, -4293.5% operating margin). On trailing 12-month operating scale, ZLAB generates $442M in USD-normalized revenue versus $6.2M for CGON. In operating R&D and SG&A reinvestment, ZLAB deploys 63.6% of Rev ($281M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CGON.

ZLAB screens cheaper on headline valuation multiples. ZLAB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.8x EV/Revenue (-59.3% EBITDA margin), whereas CGON trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ZLAB (-30.0% ROE) versus CGON (-28.3% ROE) capital efficiency.

In options market volatility and institutional positioning, ZLAB carries 58.4% implied volatility (58th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 78% Vol realized risk). By comparison, CGON carries 238.6% implied volatility (85th %ile, Extreme (>80th %ile)), a 0.35x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.77β · 86% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.